2025 Q4 -tulosraportti
Vain PDF
113 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·49 min sitten · MuokattuNo visible short in Circio, many thought it was probably short selling that was responsible for yesterday's sell-off since it was so brutal, that's not correct, has anyone managed to see who was responsible for yesterday's sell-off, or who has bought so heavily today ?
I think it was 57 million yesterday, and today 60 million. Many people here are nervous, and it continues.
·3 t sittenTHE ANALYSTS ARE SAYING THE SAME THING WE'VE BEEN SAYING ALL ALONG. 📊🧬 Analyst Group — one of Sweden's leading analysis houses for small and medium-sized companies — just released their comment on Circio. Read what they actually point to: 👇 Regarding the ESGCT selection: Circio has been selected for an oral presentation at Europe's largest gene and cell therapy conference in Hamburg in October — about circVec for next-generation T-cell therapy. Analyst Group sees it as Circio gaining visibility among potential partners "at a relevant point in development". 🎤 Regarding Dinah Sah to the board: they call it a recognition of the technology from an experienced gene and RNA therapy specialist. Not just an appointment — a validation. 👑 And then the most important thing: 🎯 They state that the H2-26 readouts — in vivo CAR-T delivery, wet AMD, heart disease model, and CNS PoC — are the most significant events in the short term. And that positive outcomes will be "progress towards a first license agreement." There you have it, in black and white from an independent third party: the path goes through this autumn's data, and the goal is the first license. 🧱 Note that Analyst Group states they are paid for the comment — this is standard for commissioned analysis, and worth knowing. They simultaneously emphasize that the company has not been allowed to influence their assessments. Still no guarantee that the data will deliver. But the path is clear, the timeline is now, and several independent voices point the same way. 👀 We know what we own. ♟️🧱🍷
4 t sittenThe H2-26 readouts, spanning in vivo CAR targeted T-cell delivery, wet AMD and heart disease-model efficacy and CNS PoC data, remain the most significant near-term events, and positive outcomes would represent progress in the direction of a first licensing agreement.
Yes, that's how it is. And the price increase today was just right for those who emphasize that.- ·4 t sittenHere is a brief summary of the comment from Analyst Group: * The selection for oral presentation at ASGCT 2026 is considered a significant quality confirmation of Circios' circVec platform, as only a few submitted abstracts receive this opportunity. * Analyst Group believes this serves as an independent scientific validation of the strong preclinical results Circio had already shown, including up to 50x higher gene expression in the eye and around 40x in the heart. * The presentation can increase visibility towards potential licensing partners and large pharmaceutical companies, especially during a period when interest in RNA technology is high following major acquisitions in the sector. * Analyst Group points out that Circio had already secured its first fully funded collaboration with a global top pharmaceutical company, and believes ASGCT provides a good arena for expanding partner dialogues. * They also highlight several upcoming value drivers, including disease model data for eye and heart, as well as new data within in vivo CAR-T. * Conclusion: Analyst Group considers the selection a clearly positive milestone that strengthens the credibility of the circVec platform and can contribute to increased interest from industry partners in the coming months.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
113 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·49 min sitten · MuokattuNo visible short in Circio, many thought it was probably short selling that was responsible for yesterday's sell-off since it was so brutal, that's not correct, has anyone managed to see who was responsible for yesterday's sell-off, or who has bought so heavily today ?I think it was 57 million yesterday, and today 60 million. Many people here are nervous, and it continues.
- ·3 t sittenTHE ANALYSTS ARE SAYING THE SAME THING WE'VE BEEN SAYING ALL ALONG. 📊🧬 Analyst Group — one of Sweden's leading analysis houses for small and medium-sized companies — just released their comment on Circio. Read what they actually point to: 👇 Regarding the ESGCT selection: Circio has been selected for an oral presentation at Europe's largest gene and cell therapy conference in Hamburg in October — about circVec for next-generation T-cell therapy. Analyst Group sees it as Circio gaining visibility among potential partners "at a relevant point in development". 🎤 Regarding Dinah Sah to the board: they call it a recognition of the technology from an experienced gene and RNA therapy specialist. Not just an appointment — a validation. 👑 And then the most important thing: 🎯 They state that the H2-26 readouts — in vivo CAR-T delivery, wet AMD, heart disease model, and CNS PoC — are the most significant events in the short term. And that positive outcomes will be "progress towards a first license agreement." There you have it, in black and white from an independent third party: the path goes through this autumn's data, and the goal is the first license. 🧱 Note that Analyst Group states they are paid for the comment — this is standard for commissioned analysis, and worth knowing. They simultaneously emphasize that the company has not been allowed to influence their assessments. Still no guarantee that the data will deliver. But the path is clear, the timeline is now, and several independent voices point the same way. 👀 We know what we own. ♟️🧱🍷
- 4 t sittenThe H2-26 readouts, spanning in vivo CAR targeted T-cell delivery, wet AMD and heart disease-model efficacy and CNS PoC data, remain the most significant near-term events, and positive outcomes would represent progress in the direction of a first licensing agreement.Yes, that's how it is. And the price increase today was just right for those who emphasize that.
- ·4 t sittenHere is a brief summary of the comment from Analyst Group: * The selection for oral presentation at ASGCT 2026 is considered a significant quality confirmation of Circios' circVec platform, as only a few submitted abstracts receive this opportunity. * Analyst Group believes this serves as an independent scientific validation of the strong preclinical results Circio had already shown, including up to 50x higher gene expression in the eye and around 40x in the heart. * The presentation can increase visibility towards potential licensing partners and large pharmaceutical companies, especially during a period when interest in RNA technology is high following major acquisitions in the sector. * Analyst Group points out that Circio had already secured its first fully funded collaboration with a global top pharmaceutical company, and believes ASGCT provides a good arena for expanding partner dialogues. * They also highlight several upcoming value drivers, including disease model data for eye and heart, as well as new data within in vivo CAR-T. * Conclusion: Analyst Group considers the selection a clearly positive milestone that strengthens the credibility of the circVec platform and can contribute to increased interest from industry partners in the coming months.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
113 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·49 min sitten · MuokattuNo visible short in Circio, many thought it was probably short selling that was responsible for yesterday's sell-off since it was so brutal, that's not correct, has anyone managed to see who was responsible for yesterday's sell-off, or who has bought so heavily today ?I think it was 57 million yesterday, and today 60 million. Many people here are nervous, and it continues.
- ·3 t sittenTHE ANALYSTS ARE SAYING THE SAME THING WE'VE BEEN SAYING ALL ALONG. 📊🧬 Analyst Group — one of Sweden's leading analysis houses for small and medium-sized companies — just released their comment on Circio. Read what they actually point to: 👇 Regarding the ESGCT selection: Circio has been selected for an oral presentation at Europe's largest gene and cell therapy conference in Hamburg in October — about circVec for next-generation T-cell therapy. Analyst Group sees it as Circio gaining visibility among potential partners "at a relevant point in development". 🎤 Regarding Dinah Sah to the board: they call it a recognition of the technology from an experienced gene and RNA therapy specialist. Not just an appointment — a validation. 👑 And then the most important thing: 🎯 They state that the H2-26 readouts — in vivo CAR-T delivery, wet AMD, heart disease model, and CNS PoC — are the most significant events in the short term. And that positive outcomes will be "progress towards a first license agreement." There you have it, in black and white from an independent third party: the path goes through this autumn's data, and the goal is the first license. 🧱 Note that Analyst Group states they are paid for the comment — this is standard for commissioned analysis, and worth knowing. They simultaneously emphasize that the company has not been allowed to influence their assessments. Still no guarantee that the data will deliver. But the path is clear, the timeline is now, and several independent voices point the same way. 👀 We know what we own. ♟️🧱🍷
- 4 t sittenThe H2-26 readouts, spanning in vivo CAR targeted T-cell delivery, wet AMD and heart disease-model efficacy and CNS PoC data, remain the most significant near-term events, and positive outcomes would represent progress in the direction of a first licensing agreement.Yes, that's how it is. And the price increase today was just right for those who emphasize that.
- ·4 t sittenHere is a brief summary of the comment from Analyst Group: * The selection for oral presentation at ASGCT 2026 is considered a significant quality confirmation of Circios' circVec platform, as only a few submitted abstracts receive this opportunity. * Analyst Group believes this serves as an independent scientific validation of the strong preclinical results Circio had already shown, including up to 50x higher gene expression in the eye and around 40x in the heart. * The presentation can increase visibility towards potential licensing partners and large pharmaceutical companies, especially during a period when interest in RNA technology is high following major acquisitions in the sector. * Analyst Group points out that Circio had already secured its first fully funded collaboration with a global top pharmaceutical company, and believes ASGCT provides a good arena for expanding partner dialogues. * They also highlight several upcoming value drivers, including disease model data for eye and heart, as well as new data within in vivo CAR-T. * Conclusion: Analyst Group considers the selection a clearly positive milestone that strengthens the credibility of the circVec platform and can contribute to increased interest from industry partners in the coming months.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt